Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
Natera, Inc., a diagnostics company, provides molecular testing services worldwide.
Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
The company also provides Signatera molecular residual disease test for assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based genomic profiling test, that provides insight into genomic alterations and biomarkers; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.
In addition, it offers Constellation, a cloud-based software product.
It serves independent laboratories, national and regional reference laboratories, medical centers and physician practices, research laboratories and pharmaceutical companies through its direct sales force, and a network of laboratory and distribution partners.
It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays.
The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012.
Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.41 Increased by +35.94% | -0.35 Decreased by -18.29% |
| Nov 12, 24 | -0.26 Increased by +72.63% | -0.57 Increased by +54.39% |
| Aug 8, 24 | -0.30 Increased by +69.07% | -0.69 Increased by +56.52% |
| May 9, 24 | -0.56 Increased by +54.47% | -0.71 Increased by +21.13% |
| Feb 28, 24 | -0.64 Increased by +53.28% | -0.73 Increased by +12.33% |
| Nov 8, 23 | -0.95 Increased by +24.00% | -0.96 Increased by +1.04% |
| Aug 3, 23 | -0.97 Increased by +35.33% | -1.09 Increased by +11.01% |
| May 9, 23 | -1.23 Increased by +15.17% | -1.15 Decreased by -6.96% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 476.06 M Increased by +53.02% | -53.77 M Increased by +31.09% | Decreased by -11.29% Increased by +54.97% |
| Sep 30, 24 | 439.76 M Increased by +63.90% | -31.59 M Increased by +71.02% | Decreased by -7.18% Increased by +82.32% |
| Jun 30, 24 | 413.35 M Increased by +58.13% | -37.46 M Increased by +66.19% | Decreased by -9.06% Increased by +78.62% |
| Mar 31, 24 | 367.74 M Increased by +52.11% | -67.60 M Increased by +50.63% | Decreased by -18.38% Increased by +67.55% |
| Dec 31, 23 | 311.11 M Increased by +43.20% | -78.03 M Increased by +45.27% | Decreased by -25.08% Increased by +61.78% |
| Sep 30, 23 | 268.31 M Increased by +27.38% | -109.03 M Increased by +10.25% | Decreased by -40.64% Increased by +29.54% |
| Jun 30, 23 | 261.40 M Increased by +31.89% | -110.80 M Increased by +23.66% | Decreased by -42.39% Increased by +42.12% |
| Mar 31, 23 | 241.76 M Increased by +24.53% | -136.94 M Increased by +1.20% | Decreased by -56.64% Increased by +20.66% |